No Cure, 1.4 Million Patients. Terremoto Has $108M to Try.

Terremoto Biosciences raises $108M Series C to advance a potential first-in-class therapy for HHT, a rare inherited vascular disease

18 May 2026

A $108 million Series C closed April 15 for Terremoto Biosciences, pulling in new backers RA Capital Management, Deep Track Capital, and BeOne Medicines alongside existing investors OrbiMed, Third Rock Ventures, Novo Holdings, and Cormorant Asset Management. Two programs head into Phase 1 trials: TER-2013 in oncology and TER-4480, aimed at hereditary hemorrhagic telangiectasia, a rare inherited vascular disorder affecting 1.4 million people worldwide with no approved treatment.

What makes that absence so striking is the severity of what patients face. HHT causes faulty blood vessel formation throughout the body, driving recurrent bleeds and progressive damage to the lungs, liver, and brain. Care today means invasive procedures and stopgap measures. Nothing touches the underlying disease. By selectively blocking AKT1, a signaling protein preclinical research has identified as the primary driver of abnormal vessel growth, TER-4480 is designed to change that.

Earlier drugs targeting the same PI3K/AKT pathway hit multiple isoforms at once and paid for it with side effects including rash and blood sugar disruption. In a chronic disease requiring lifelong management, that toxicity profile is a serious liability. By zeroing in on AKT1 and leaving AKT2 alone, Terremoto is betting precision can unlock what broader inhibition could not.

Caution is still warranted. Phase 1 results for TER-4480 are not expected until 2027, and the PI3K/AKT pathway has a long record of clinical disappointments.

Orphan drug revenues are projected to surpass $400 billion globally by 2032, and capital is concentrating around platforms where scientific focus and patient need intersect. For Terremoto, HHT fits that profile cleanly. For the 1.4 million people still waiting on a real treatment, entering the clinic is the most concrete reason for hope they have had yet.